Dr Jitendra Singh Inaugurates Recombinant Cell Facility At BRIC-RGCB
ECONOMY & POLICY

Dr Jitendra Singh Inaugurates Recombinant Cell Facility At BRIC-RGCB

Union Minister Dr Jitendra Singh inaugurated the Central Facility for Recombinant Cells and Sensors at BRIC-Rajiv Gandhi Centre for Biotechnology in Thiruvananthapuram, Keralam, noting the facility will accelerate target-specific drug discovery and support medical and agricultural genomics. The minister also announced the foundation stone for a dedicated GMP facility and released a book by Professor V.P.N. Nampoori. The new facility was developed with investment of Rs 60 crores, equivalent to 600 million (600 mn) and is intended to serve academia, industry and healthcare innovators.

He outlined a vision for a bio-driven economy supported by the BioE3 Policy, which aims to align economy, environment and employment to boost biomanufacturing. He cited that India’s bioeconomy has grown 16-fold in the past decade from 10 billion US dollars (10 bn US dollars) to nearly 166 billion US dollars (166 bn US dollars) and is aiming for 300 billion US dollars (300 bn US dollars). The policy emphasis is intended to anticipate and enable a shift towards large-scale biomanufacturing and bio-based industries.

He highlighted growth in entrepreneurship with the number of biotechnology start-ups rising from about 50 to 70 in 2014 to over 11,000, reflecting an expanding innovation ecosystem supported by policy reforms and funding for deep-tech start-ups. The Department of Biotechnology has funded the new recombinant cell facility through long-term programmes. He emphasised the rising burden of non-communicable diseases and the institute's research in cancer biology, preventive healthcare and HPV vaccination evidence.

He announced that the GMP facility will support pre-commercial production of biologics and cell-based therapies, including CAR-T therapy, and will operate on a pay-and-use basis for biotech industries with implementation in two phases and total DBT investment of Rs 80 crores, equivalent to 800 million (800 mn). He called for deeper collaboration among research institutions, private industry and emerging sectors such as nuclear medicine and deep-ocean research, encouraging coastal states to align biotechnology with national missions. He urged young researchers to utilise the expanding ecosystem and assured continued government support for innovation and interdisciplinary collaboration.

Union Minister Dr Jitendra Singh inaugurated the Central Facility for Recombinant Cells and Sensors at BRIC-Rajiv Gandhi Centre for Biotechnology in Thiruvananthapuram, Keralam, noting the facility will accelerate target-specific drug discovery and support medical and agricultural genomics. The minister also announced the foundation stone for a dedicated GMP facility and released a book by Professor V.P.N. Nampoori. The new facility was developed with investment of Rs 60 crores, equivalent to 600 million (600 mn) and is intended to serve academia, industry and healthcare innovators. He outlined a vision for a bio-driven economy supported by the BioE3 Policy, which aims to align economy, environment and employment to boost biomanufacturing. He cited that India’s bioeconomy has grown 16-fold in the past decade from 10 billion US dollars (10 bn US dollars) to nearly 166 billion US dollars (166 bn US dollars) and is aiming for 300 billion US dollars (300 bn US dollars). The policy emphasis is intended to anticipate and enable a shift towards large-scale biomanufacturing and bio-based industries. He highlighted growth in entrepreneurship with the number of biotechnology start-ups rising from about 50 to 70 in 2014 to over 11,000, reflecting an expanding innovation ecosystem supported by policy reforms and funding for deep-tech start-ups. The Department of Biotechnology has funded the new recombinant cell facility through long-term programmes. He emphasised the rising burden of non-communicable diseases and the institute's research in cancer biology, preventive healthcare and HPV vaccination evidence. He announced that the GMP facility will support pre-commercial production of biologics and cell-based therapies, including CAR-T therapy, and will operate on a pay-and-use basis for biotech industries with implementation in two phases and total DBT investment of Rs 80 crores, equivalent to 800 million (800 mn). He called for deeper collaboration among research institutions, private industry and emerging sectors such as nuclear medicine and deep-ocean research, encouraging coastal states to align biotechnology with national missions. He urged young researchers to utilise the expanding ecosystem and assured continued government support for innovation and interdisciplinary collaboration.

Related Stories

Gold Stories

Next Story
Resources

Schindler named among Forbes’ World’s Best Employers 2026

Schindler has been named among Forbes’ World’s Best Employers 2026, a global ranking recognising companies for their workplace environments.Compiled by Forbes in partnership with Statista, the ranking is based on independent employee feedback, including whether employees would recommend their organisation to friends and family.The company said the recognition reflected its focus on creating a workplace where employees can develop their expertise and build careers. ..

Next Story
Infrastructure Urban

India needs an export-execution mindset: Vishesh Jain

Interview with Vishesh Jain, Founder & CEO, EximpleWhat gaps in India’s global trade ecosystem led you to build Eximple, and what problem did you see businesses struggling with most?Eximple came out of a problem that all three founders had seen from different choke points in the trade ecosystem. India has millions of MSMEs and manufacturers, and many of them can make products that are genuinely competitive on quality. Yet only a small fraction is able to build meaningful international businesses. In our experience, the gap is usually not manufacturing capability; it is the ability to exe..

Next Story
Building Material

Nuvoco reports 13.5% revenue growth in Q2 FY27

Nuvoco Vistas Corp. Ltd. reported consolidated revenue of Rs 27.9 billion for Q2 FY27, up 13.5% year on year. Cement sales volume rose 9% to 4.7 million tonnes (MMT), while EBITDA increased 11% to Rs 4.11 billion.The company said it began its cement operations in 2014 with a 2.3 MMT per annum (MMTPA) operation at Nimbol. It now aims to reach 35 MMTPA of cement capacity by FY28, nearly 15 times its initial capacity. Its portfolio spans cement, ready-mix concrete and modern building materials.On sustainability and cost efficiency, Nuvoco partnered with CleanMax for a 46.4 MW wind-solar hybrid re..

Advertisement

Subscribe to Our Newsletter

Get daily newsletters around different themes from Construction world.

STAY CONNECTED

Advertisement

SPECIAL OFFER
QR Code